Update your location to show providers, locations, and services closest to you.
Neurosurgeon, Neurovascular Surgeon
My name is Brian Hoh, MD, MBA, and I am chair of the UF Department of Neurosurgery. I specialize in the treatment of brain aneurysms, arteriovenous malformations, ischemic and hemorrhagic stroke, cavernous malformations, carotid stenosis, moyamoya disease, hydrocephalus, Chiari malformation, brain cysts and brain tumors, including meningiomas, glioblastoma and astrocytomas.
I joined the UF Department of Neurosurgery in 2006. Before that, I graduated with a bachelor’s degree from Stanford University and a medical degree from Columbia University. I completed my internship in surgery, residency in neurosurgery, and fellowship in endovascular neurosurgery and interventional neuroradiology at Harvard University’s teaching hospital, Massachusetts General Hospital. I later attended UF business school and graduated with an MBA in 2019.
In addition to taking care of patients, I conduct NIH-funded laboratory and clinical research to improve biomedical advances in care. My laboratory investigates the biological mechanisms of brain aneurysm formation and rupture, innovative tissue engineering technology to improve the treatment of brain aneurysms, and the pathophysiology of acute neural injury and delayed cerebral ischemia after subarachnoid hemorrhage.
The NIH awarded me a $38 million grant to lead a large national clinical trial, Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA). With CAPTIVA, we are investigating rivaroxaban or ticagrelor versus clopidogrel for preventing stroke in patients with symptomatic 70% or greater intracranial atherosclerotic stenosis.
As a national leader in neurosurgery, I have served as president of the Congress of Neurological Surgeons, chair of the Joint American Association of Neurological Surgeons/Congress of Neurosurgical Surgeons Cerebrovascular Section, co-chair of the editorial board of the Journal of Neurosurgery and a past member of the editorial board of World Neurosurgery.
In my free time, I enjoy spending time with my family, rooting for the Gators and playing golf.
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Emergency personnel arrived at Paul Dell’s home, where his wife led them upstairs. They found him sitting upright in a chair, unable to say his name, age or…
December 6, 2023
With $1 million in support from University of Florida President Ben Sasse’s strategic funding initiative, investigators at the Evelyn F. and William L.…
AI at UF, Department of Neurosurgery, +3 more
